Summary
Product description
The Competitive Intelligence Report Peroxisome Proliferator-Activated Receptor (PPAR) Agonists as of November 2008 provides a competitor analysis in the development pipeline of novel PPAR alpha, gamma and delta agonists for treatment of dyslipidemia or type 2 diabetes or obesity.
Peroxisome proliferator-activated receptors (PPARs) are members of a nuclear receptor superfamily which regulate gene expression and, thereby, controll energy metabolism. PPAR gamma has a key role in adipogenesis, insulin sensitivity, and glucose and lipid metabolism, and also plays a major role in vascular biology. Thiazolidinediones (TZDs) are the ligands of PPAR gamma. Rosiglitazone and pioglitazone are established and economically successful PPAR gamma agonists with combined 2007 sales of about US$ 6.6 bln explaining the high interest in next generation products. The thiazolidinedione's (TZDs) recently found themselves in the spotlight when the safety of GlaxoSmithKline's rosiglitazone was brought into question by a meta-analysis that associated it with increased risk of myocardial ischemic events.
As a consequence, sales of GSKs rosiglitzone declined by more than 20 %, but for the benefit of Takedas pioglitzone which raised by 23 %. A number of next generation PPAR gamma agonists are in clinical development, some of them including PPAR alpha agonistic action in a balanced manner. A new area of interest are PPAR agonists targeting the delta receptor or including it in dual or triple PPAR agonist approaches. The PPAR alpha agonist fenofibrate from Solvay Pharmaceuticals and Abbott yielded 2007 sales of US$ 1.9 bln. Next generation products are in advanced development to stop generic erosion of branded product sales.
The report provides a compilation of current active projects in research and development of novel PPAR agonists. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- Additional comments with a hyperlink leading to the source of information.
|
